{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:28:40Z","timestamp":1789986520610,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vitamin deficiency syndromes and blood\u2013brain barrier (BBB) dysfunction are frequent phenomena in psychiatric conditions. We analysed the largest available first-episode schizophrenia-spectrum psychosis (FEP) cohort to date regarding routine cerebrospinal fluid (CSF) and blood parameters to investigate the association between vitamin deficiencies (vitamin B12 and folate) and BBB impairments in FEP. We report a retrospective analysis of clinical data from all inpatients that were admitted to our tertiary care hospital with an ICD-10 diagnosis of a first-episode F2x (schizophrenia-spectrum) between January 1, 2008 and August 1, 2018 and underwent a lumbar puncture, blood-based vitamin status diagnostics and neuroimaging within the clinical routine. 222 FEP patients were included in our analyses. We report an increased CSF\/serum albumin quotient (Qalb) as a sign of BBB dysfunction in 17.1% (38\/222) of patients. White matter lesions (WML) were present in 29.3% of patients (62\/212). 17.6% of patients (39\/222) showed either decreased vitamin B12 levels or decreased folate levels. No statistically significant association was found between vitamin deficiencies and altered Qalb. This retrospective analysis contributes to the discussion on the impact of vitamin deficiency syndromes in FEP. Although decreased vitamin B12 or folate levels were found in approximately 17% of our cohort, we found no evidence for significant associations between BBB dysfunction and vitamin deficiencies. To strengthen the evidence regarding the clinical implications of vitamin deficiencies in FEP, prospective studies with standardized measurements of vitamin levels together with follow-up measurements and assessment of symptom severity in addition to CSF diagnostics are needed.<\/jats:p>","DOI":"10.1007\/s00406-023-01572-3","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T22:02:37Z","timestamp":1677880957000},"page":"1693-1701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Blood\u2013brain barrier dysfunction and folate and vitamin B12 levels in first-episode schizophrenia-spectrum psychosis: a retrospective chart review"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4596-4287","authenticated-orcid":false,"given":"Mattia","family":"Campana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"L\u00f6hrs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Strau\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"M\u00fcnz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Oviedo-Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyumi","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Maurus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Raabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Moussiopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Eichhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Falkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkomiet","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,4]]},"reference":[{"issue":"4","key":"1572_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1192\/bjo.2018.27","volume":"4","author":"TA Pollak","year":"2018","unstructured":"Pollak TA, Lennox BR (2018) Time for a change of practice: the real-world value of testing for neuronal autoantibodies in acute first-episode psychosis. BJPsych Open 4(4):262\u2013264","journal-title":"BJPsych Open"},{"issue":"24","key":"1572_CR2","first-page":"412","volume":"117","author":"A Hasan","year":"2020","unstructured":"Hasan A et al (2020) Schizophrenia. Dtsch Arztebl Int 117(24):412\u2013419","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"1572_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2215-0366(16)30375-3","volume":"4","author":"BR Lennox","year":"2017","unstructured":"Lennox BR et al (2017) Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study. Lancet Psychiatry 4(1):42\u201348","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"1572_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/mp.2015.35","volume":"20","author":"P Falkai","year":"2015","unstructured":"Falkai P et al (2015) Kraepelin revisited: schizophrenia from degeneration to failed regeneration. Mol Psychiatry 20(6):671\u2013676","journal-title":"Mol Psychiatry"},{"issue":"6301","key":"1572_CR5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.aag2590","volume":"353","author":"RM Ransohoff","year":"2016","unstructured":"Ransohoff RM (2016) How neuroinflammation contributes to neurodegeneration. Science 353(6301):777\u2013783","journal-title":"Science"},{"issue":"6","key":"1572_CR6","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41380-018-0220-4","volume":"24","author":"S Orlovska-Waast","year":"2019","unstructured":"Orlovska-Waast S et al (2019) Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. Mol Psychiatry 24(6):869\u2013887","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1572_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S2215-0366(17)30293-6","volume":"5","author":"TA Pollak","year":"2018","unstructured":"Pollak TA et al (2018) The blood-brain barrier in psychosis. Lancet Psychiatry 5(1):79\u201392","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"1572_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nn.3922","volume":"18","author":"The Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium","year":"2015","unstructured":"The Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium (2015) Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci 18(2):199\u2013209","journal-title":"Nat Neurosci"},{"issue":"9","key":"1572_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1468-1331.2006.01493.x","volume":"13","author":"F Deisenhammer","year":"2006","unstructured":"Deisenhammer F et al (2006) Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol 13(9):913\u2013922","journal-title":"Eur J Neurol"},{"issue":"6","key":"1572_CR10","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1007\/s00415-010-5876-x","volume":"258","author":"S Jesse","year":"2011","unstructured":"Jesse S et al (2011) Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. J Neurol 258(6):1034\u20131041","journal-title":"J Neurol"},{"issue":"1","key":"1572_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41398-020-00967-3","volume":"10","author":"D Endres","year":"2020","unstructured":"Endres D et al (2020) Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis. Transl Psychiatry 10(1):279","journal-title":"Transl Psychiatry"},{"key":"1572_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/schbul\/sbab105","volume":"48","author":"M Campana","year":"2021","unstructured":"Campana M et al (2021) Cerebrospinal fluid pathologies in schizophrenia-spectrum disorder-A retrospective chart review. Schizophr Bull 48:47\u201355","journal-title":"Schizophr Bull"},{"key":"1572_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/B978-0-12-381980-2.00017-7","volume-title":"The Vitamins","author":"GF Combs","year":"2012","unstructured":"Combs GF (2012) Chapter 17\u2014Vitamin B12. In: Combs GF (ed) The Vitamins. Elsevier, The Netherlands, pp 377\u2013394"},{"issue":"11","key":"1572_CR14","doi-asserted-by":"publisher","first-page":"5923","DOI":"10.1073\/pnas.94.11.5923","volume":"94","author":"SA Lipton","year":"1997","unstructured":"Lipton SA et al (1997) Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 94(11):5923\u20135928","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"1572_CR15","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2011-02-338269","volume":"118","author":"RS Beard","year":"2011","unstructured":"Beard RS, Reynolds JJ, Bearden SE (2011) Hyperhomocysteinemia increases permeability of the blood-brain barrier by NMDA receptor-dependent regulation of adherens and tight junctions. Blood 118(7):2007\u20132014","journal-title":"Blood"},{"issue":"2","key":"1572_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1385\/BTER:98:2:109","volume":"98","author":"M Yanik","year":"2004","unstructured":"Yanik M et al (2004) Plasma manganese, selenium, zinc, copper, and iron concentrations in patients with schizophrenia. Biol Trace Elem Res 98(2):109\u2013117","journal-title":"Biol Trace Elem Res"},{"issue":"1\u20132","key":"1572_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.psychres.2009.01.013","volume":"175","author":"A Kale","year":"2010","unstructured":"Kale A et al (2010) Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Res 175(1\u20132):47\u201353","journal-title":"Psychiatry Res"},{"issue":"10","key":"1572_CR18","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1210\/jc.2014-1887","volume":"99","author":"G Valipour","year":"2014","unstructured":"Valipour G, Saneei P, Esmaillzadeh A (2014) Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies. J Clin Endocrinol Metab 99(10):3863\u20133872","journal-title":"J Clin Endocrinol Metab"},{"key":"1572_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psychres.2016.03.003","volume":"245","author":"B Cao","year":"2016","unstructured":"Cao B et al (2016) Lower folate levels in schizophrenia: a meta-analysis. Psychiatry Res 245:1\u20137","journal-title":"Psychiatry Res"},{"issue":"1","key":"1572_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/archpsyc.64.1.31","volume":"64","author":"AS Brown","year":"2007","unstructured":"Brown AS et al (2007) Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry 64(1):31\u201339","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"1572_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/eip.12122","volume":"9","author":"KA Graham","year":"2015","unstructured":"Graham KA et al (2015) Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early Interv Psychiatry 9(5):397\u2013405","journal-title":"Early Interv Psychiatry"},{"issue":"2","key":"1572_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.pscychresns.2015.06.006","volume":"233","author":"V Shivakumar","year":"2015","unstructured":"Shivakumar V et al (2015) Serum vitamin D and hippocampal gray matter volume in schizophrenia. Psychiatry Res 233(2):175\u2013179","journal-title":"Psychiatry Res"},{"issue":"3","key":"1572_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000071002","volume":"16","author":"M Lehmann","year":"2003","unstructured":"Lehmann M et al (2003) Vitamin B12-B6-folate treatment improves blood-brain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment. Dement Geriatr Cogn Disord 16(3):145\u2013150","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"1572_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.biopsych.2018.12.018","volume":"86","author":"K Allott","year":"2019","unstructured":"Allott K et al (2019) The vitamins in psychosis study: a randomized, double-blind, placebo-controlled trial of the effects of vitamins B(12), B(6), and folic acid on symptoms and neurocognition in first-episode psychosis. Biol Psychiatry 86(1):35\u201344","journal-title":"Biol Psychiatry"},{"issue":"5","key":"1572_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2013.900","volume":"70","author":"JL Roffman","year":"2013","unstructured":"Roffman JL et al (2013) Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiat 70(5):481\u2013489","journal-title":"JAMA Psychiat"},{"issue":"9","key":"1572_CR26","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1017\/S0033291717000022","volume":"47","author":"J Firth","year":"2017","unstructured":"Firth J et al (2017) The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis. Psychol Med 47(9):1515\u20131527","journal-title":"Psychol Med"},{"key":"1572_CR27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1515\/labm.1994.18.12.545","volume":"18","author":"C Trendelenburg","year":"1994","unstructured":"Trendelenburg C (1994) Labormedizinische Spezialbefundung und \u00e4rztliche Verantwortung. Laboratoriumsmedizin 18:545\u2013551","journal-title":"Laboratoriumsmedizin"},{"issue":"7","key":"1572_CR28","doi-asserted-by":"publisher","first-page":"e0181431","DOI":"10.1371\/journal.pone.0181431","volume":"12","author":"E Bernitsas","year":"2017","unstructured":"Bernitsas E et al (2017) Cerebrospinal fluid humoral immunity in the differential diagnosis of multiple sclerosis. PLoS ONE 12(7):e0181431","journal-title":"PLoS ONE"},{"issue":"8","key":"1572_CR29","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/jnnp.57.8.897","volume":"57","author":"M Andersson","year":"1994","unstructured":"Andersson M et al (1994) Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 57(8):897\u2013902","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"1572_CR30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/archneur.62.6.865","volume":"62","author":"MS Freedman","year":"2005","unstructured":"Freedman MS et al (2005) Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 62(6):865\u2013870","journal-title":"Arch Neurol"},{"issue":"9","key":"1572_CR31","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1515\/cclm-2016-0804","volume":"55","author":"S Ferraro","year":"2017","unstructured":"Ferraro S, Panzeri A, Panteghini M (2017) Tackling serum folate test in European countries within the health technology assessment paradigm: request appropriateness, assays and health outcomes. Clin Chem Lab Med 55(9):1262\u20131275","journal-title":"Clin Chem Lab Med"},{"key":"1572_CR32","unstructured":"Cobalamin RC (2014) Vitamin B12, in Modern Nutrition in Health and Disease 11th ed., C.B. Ross AC, Cousins RJ, Tucker KL, Ziegler TR, (Editor), Lippincott Williams & Wilkins, Baltimore, 369\u201389."},{"issue":"1","key":"1572_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00394-015-1079-7","volume":"56","author":"R Schupbach","year":"2017","unstructured":"Schupbach R et al (2017) Micronutrient status and intake in omnivores, vegetarians and vegans in Switzerland. Eur J Nutr 56(1):283\u2013293","journal-title":"Eur J Nutr"},{"key":"1572_CR34","unstructured":"Johnson, L. Vitamin B12 Deficiency. 2020."},{"issue":"3","key":"1572_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1552-6569.2006.00047.x","volume":"16","author":"RO Hopkins","year":"2006","unstructured":"Hopkins RO et al (2006) Prevalence of white matter hyperintensities in a young healthy population. J Neuroimaging 16(3):243\u2013251","journal-title":"J Neuroimaging"},{"key":"1572_CR36","doi-asserted-by":"publisher","first-page":"9372050","DOI":"10.1155\/2017\/9372050","volume":"2017","author":"J Lin","year":"2017","unstructured":"Lin J et al (2017) Multiple factors involved in the pathogenesis of white matter lesions. Biomed Res Int 2017:9372050","journal-title":"Biomed Res Int"},{"key":"1572_CR37","unstructured":"(DGPPN) Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie (2019) S3-Leitlinie Schizophrenie. AWMF-Register Nr. 038\u2013009. www.awmf.org\/leitlinien\/detail\/ll\/038-009.html."},{"key":"1572_CR38","unstructured":"(2014) Psychosis and Schizophrenia in Adults: Treatment and Management. NICE Clinical Guideline 178, http:\/\/www.nice.org.uk\/guidance\/cg178\/evidence\/cg178-psychosis-and-schizophrenia-in-adults-full-guideline3, 2014."},{"key":"1572_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fmolb.2016.00027","volume":"3","author":"L Hannibal","year":"2016","unstructured":"Hannibal L et al (2016) Biomarkers and Algorithms for the Diagnosis of Vitamin B12 Deficiency. Front Mol Biosci 3:27","journal-title":"Front Mol Biosci"},{"key":"1572_CR40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.canep.2015.12.007","volume":"40","author":"JF Arendt","year":"2016","unstructured":"Arendt JF et al (2016) Elevated plasma vitamin B12 levels and cancer prognosis: a population-based cohort study. Cancer Epidemiol 40:158\u2013165","journal-title":"Cancer Epidemiol"},{"issue":"11","key":"1572_CR41","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1515\/CCLM.2003.227","volume":"41","author":"W Herrmann","year":"2003","unstructured":"Herrmann W et al (2003) Functional vitamin B12 deficiency and determination of holotranscobalamin in populations at risk. Clin Chem Lab Med 41(11):1478\u20131488","journal-title":"Clin Chem Lab Med"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-023-01572-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-023-01572-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-023-01572-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T14:04:45Z","timestamp":1702303485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-023-01572-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,4]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1572"],"URL":"https:\/\/doi.org\/10.1007\/s00406-023-01572-3","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,4]]},"assertion":[{"value":"10 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Campana, L. L\u00f6hrs, J. Strau\u00df, S. M\u00fcnz, P. Fernando, T. Oviedo-Salcedo, I. Maurus, F. Raabe, J. Moussiopoulou and P. Eichhorn report no conflicts of interest. E. Wagner has been invited to Recordati advisory board meetings.\u00a0P. Falkai was honorary speaker for Janssen-Cilag, Astra-Zeneca, Eli Lilly, Bristol Myers-Squibb, Lundbeck, Pfizer, Bayer Vital, SmithKline Beecham, Wyeth, and Essex. During the last 5\u00a0years, but not presently, he was a member of the advisory boards of Janssen, AstraZeneca, Eli Lilly, and Lundbeck. A. Hasan has been invited to scientific meetings by Lundbeck, Janssen-Cilag, and Pfizer, and he received paid speakerships from Janssen, Recordati, Otsuka and Lundbeck. He was a member of Roche, Otsuka, Lundbeck, Rovi, Recordati and Janssen advisory boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study was approved by the university ethics committee (registration number: 18\u2013570).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}